Randomised clinical trial to assess the efficacy of a multifactorial intervention in order to reduce hospitalisation and improve quality of life in patients with heart failure

Submission date 03/11/2004	Recruitment status No longer recruiting	Prospectively registered[X] Protocol
Registration date 01/02/2005	Overall study status Completed	 [] Statistical analysis plan [X] Results
Last Edited 23/07/2009	Condition category Circulatory System	Individual participant data

Plain English summary of protocol Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Dr Carlos Brotons

Contact details Sardenya Primary Care Center Sardenya 466 Barcelona Spain 08025 +34 93 56 74 380 cbrotons@eapsardenya.net

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Acronym IC-DOM

Study objectives

To assess the efficacy of a multidisciplinary non-pharmacologic intervention to reduce mortality and rehospitalisation, and to improve quality of life in patients with heart failure.

Ethics approval required Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Prevention

Participant information sheet

Health condition(s) or problem(s) studied Heart Failure

Interventions

A multidisciplinary approach to patient education and counselling, optimisation of the treatments (drugs, diet, exercise), monitorisation of the electrolyte concentrations if necessary, and teaching education on self monitoring and management. The number of scheduled home visits will be 12 (every month), with telephone calls every 15 days.

Control:

Patients in the control group will be assigned to conventional care receiving standard treatments.

Intervention Type

Other

Phase Not Specified

Primary outcome measure

The combination of cardiovascular mortality and rehospitalisations (emergency room and/or hospital) at one year.

Secondary outcome measures

- 1. Total mortality or rehospitalisation for any reason
- 2. Rehospitalisation due to heart failure
- 3. Time until rehospitalisation
- 4. Days of hospitalisation
- 5. Quality of life related to health

Statistical models to be used will be survival analysis and Cox regression.

Overall study start date 01/01/2004

Completion date 30/09/2006

Eligibility

Key inclusion criteria

400 patients recruited from four hospitals in Catalonia: Vall dHebron Hospital, Clínic Hospital, Dos de Maig Hospital and Vic Hospital.

Inclusion Criteria:

Males and females without any limit of age, discharged from the hospital with the diagnosis of heart failure following the criteria of the European Society of Cardiology.

Participant type(s) Patient

Age group

Adult

Sex Both

Target number of participants 400

Key exclusion criteria

1. Patients with heart failure due to reversible causes (hyperthyroidism, tachyarrhythmia, valve disease candidate for surgery)

2. Patients with concomitant chronic disease (cancer, chronic renal failure etc.)

3. Patients with poor mental function or any other reason to expect that the patient may have difficulty in complying with the requirements of the study

Date of first enrolment 01/01/2004

Date of final enrolment 30/09/2006

Locations

Countries of recruitment Spain

Study participating centre Sardenya Primary Care Center Barcelona Spain 08025

Sponsor information

Organisation

Sardenya Primary Care Center (Spain) - in collaboration with the Catalan Foundation Institute of Pharmacology

Sponsor details

Sardenya 466 Barcelona Spain 08025 +34 93 56 74 380 cbrotons@eapsardenya.net

Sponsor type

Hospital/treatment centre

Funder(s)

Funder type Government

Funder Name

Catalan Department of Health (Agencia d'Avaluacio de Tecnologia i Recerca Mèdiques) (Spain)

Funder Name Educational grants from:

Funder Name 1. Pfizer (Spain)

Funder Name 2. Almirall-Prodesfarma SA (Spain)

Funder Name 3. Sanofi-Synthelabo (Spain)

Funder Name 4. AstraZeneca (Spain)

Funder Name 5. Novartis (Spain)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not provided at time of registration

Study outputs

Output type

Details Dat

Date created

Date added P

Peer reviewed?

Patient-facing?

Protocol article	protocol	30/09/2005	Yes	No
Results article	results	01/04/2009	Yes	No